On October 2, INNOVENT BIO fell 3.47% in regular trading, trading at HK$92.9/share, with turnover of HK$90.83 million.

Within the Biotechnology sector where INNOVENT BIO belongs, the overall sector was under notable pressure. Among individual stocks, BEONE MEDICINES down 7.01%, 3SBIO down 5.67%, SKB BIO down 4.52%, AKESO down 2.85%, HENLIUS down 2.05%.

INNOVENT BIO is a leading biopharmaceutical company principally engaged in the research, development, manufacturing, and commercialization of innovative drugs for major diseases including oncology, cardiovascular and metabolic disorders, autoimmune conditions, and ophthalmology. Its drug modalities include monoclonal antibodies, multispecific antibodies, immune cytokines, antibody-drug conjugates, cell therapies, and small molecules. Key products include sintilimab injection, bevacizumab injection, adalimumab injection, rituximab injection, and pemigatinib tablets, with operations spanning both domestic and overseas markets.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)